These findings substantiate that the combination of berberine and evodiamine exerts its anti-obesity effects, which are mechanistically linked to the activation of the FGF21/PGC-1α signaling pathway and the subsequent promotion of adipose tissue browning. The gene discussed is PPARGC1A; the disease is obesity due to melanocortin 4 receptor deficiency.